1. Home
  2. XYF vs SABS Comparison

XYF vs SABS Comparison

Compare XYF & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

XYF

X Financial each representing six

HOLD

Current Price

$5.25

Market Cap

224.3M

Sector

Finance

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$4.18

Market Cap

198.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XYF
SABS
Founded
2014
2014
Country
China
United States
Employees
N/A
63
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.3M
198.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
XYF
SABS
Price
$5.25
$4.18
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.80
AVG Volume (30 Days)
258.2K
465.5K
Earning Date
03-18-2026
03-27-2026
Dividend Yield
10.97%
N/A
EPS Growth
49.84
N/A
EPS
5.72
N/A
Revenue
$1,106,908,607.00
$114,698.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.92
N/A
Revenue Growth
47.14
N/A
52 Week Low
$4.93
$1.00
52 Week High
$20.36
$6.60

Technical Indicators

Market Signals
Indicator
XYF
SABS
Relative Strength Index (RSI) 32.71 45.22
Support Level $4.93 $4.27
Resistance Level $5.40 $4.68
Average True Range (ATR) 0.32 0.26
MACD -0.01 -0.03
Stochastic Oscillator 14.73 15.12

Price Performance

Historical Comparison
XYF
SABS

About XYF X Financial each representing six

X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, and guarantee services provided.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: